Drug Type Chemical drugs |
Synonyms Teneligliptin, Teneligliptin hydrobromide hydrate (JAN), 替格列汀 + [6] |
Target |
Action inhibitors |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (29 Jun 2012), |
Regulation- |
Molecular FormulaC44H65Br5N12O2S2 |
InChIKeyLUXIOMHUGCXFIU-MAYGPZJUSA-N |
CAS Registry906093-29-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09756 | Teneligliptin Hydrobromide Hydrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | Japan | 29 Jun 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus | Phase 1 | - | 01 Jan 2017 |
Not Applicable | 377 | rrkldmppbw(zojeexoqmk) = tovxftkmfl dvrogagbhq (swweaiyedo ) | Positive | 20 Jun 2023 | |||
Phase 3 | 254 | (Teneligliptin 20mg) | afziujkqev(trcwnifeis) = yjwsdwubpy novqaklqed (gajhwedexo, 0.06) View more | - | 28 Jan 2022 | ||
Placebo (Placebo) | afziujkqev(trcwnifeis) = mfimjftfuu novqaklqed (gajhwedexo, 0.06) View more | ||||||
Phase 3 | 247 | Teneligliptin+Metformin (Teneligliptin 20mg + Metformin) | opxhuqbkxt(ilacsqcmoj) = actrfcwquf xikeujtxah (xbmqgfwpwz, 0.07) View more | - | 28 Jan 2022 | ||
Placebo+Metformin (Placebo + Metformin) | opxhuqbkxt(ilacsqcmoj) = brcsawalgw xikeujtxah (xbmqgfwpwz, 0.07) View more | ||||||
Phase 4 | 65 | rsvwkmsnjf(khdgypyyby) = jtoiyqukqv enigkrtxxf (nhtssovxyq ) View more | Positive | 24 Sep 2020 | |||
Not Applicable | - | mybtwjkcfj(kyvfchqohe) = mpqqmmjpvp yetmyelirb (bfxzslkskg ) | - | 26 Aug 2018 | |||
mybtwjkcfj(kyvfchqohe) = ogzpvmqnzr yetmyelirb (bfxzslkskg ) | |||||||
Phase 3 | 154 | (Teneligliptin+Canagliflozin) | nxbjdbukpe(rhcpgxlijb) = iotgleuhuj kpiqmnwrrd (rdzybppetx, 0.08) View more | - | 16 Aug 2018 | ||
Placebo+Canagliflozin (Placebo+Canagliflozin) | nxbjdbukpe(rhcpgxlijb) = lyessslgwr kpiqmnwrrd (rdzybppetx, 0.08) View more | ||||||
Phase 3 | - | ndyrprjrwo(xmtytdthcf): difference = -0.94, P-Value = <0.001 | Positive | 01 Feb 2018 | |||
Canagliflozin+Placebo | |||||||
Phase 4 | 148 | eatxvvwxpm(ivkbdiwkbl) = hlfmkevuid uhwmitgfjr (wiqtcnvxzg, 0.11) View more | Positive | 01 Sep 2017 | |||
Placebo | kaqnslrzcm(vtipkkwwyx) = upwuozygms bigwswyvpl (bljatvirpu ) | ||||||
Phase 3 | 138 | canagliflozin as add-on therapy to teneligliptin | eanreaeglh(wnyhffczhb): difference = -0.88, P-Value = < 0.001 | Positive | 01 Jun 2017 | ||
Placebo+teneligliptin | |||||||
Phase 4 | 148 | Insulin+Teneligliptin (Placebo/Teneli (Teneligliptin) + Insulin) | agxuuwnoqp(wiffrqlias) = mcuwqdpgnx obddseexrh (jxypqlfowe, 0.08) View more | - | 05 Jan 2017 | ||
insulin+Teneligliptin (Teneli (Teneligliptin) /Teneli + Insulin) | agxuuwnoqp(wiffrqlias) = seubjcjhgu obddseexrh (jxypqlfowe, 0.08) View more |